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Question: I ordered serologic testing for Lyme disease for one of my patients and I’m not sure 
how to interpret the results of the Western blot. The blot shows a few dark bands, but the report 
indicates it is not sufficient to definitively diagnose Lyme disease. Is it possible to have a “partial 
positive” result? 
 
 
Answer: A definitive diagnosis of Lyme 
disease can be challenging in the absence of 
the classic erythema migrans rash. Unlike 
erlichiosis or babesiosis, which can be easily 
identified by molecular methodologies like 
PCR, Lyme disease is most often diagnosed 
via serologic techniques. The CDC 
recommends a two-step approach to 
serologic diagnosis. The first step is a 
sensitive screening test, such as an EIA or 
ELISA, to determine whether the patient’s 
serum contains antibodies to Borrelia 
burgdorferi. If the results of the screening 
test are positive or equivocal, the second 
step – a Western blot – is performed. The 
Western blot has a higher specificity than 
the EIA or ELISA and is useful for ruling 
out any false-positives detected by the 
screening test. 
A Western blot can be used to 
identify the presence of either IgM or IgG 
antibodies to Borrelia surface proteins in the 
patient’s serum. A blot may be positive for 
IgM as early as 1-2 weeks after inoculation 
with Borrelia, whereas an IgG blot may not 
detect antibodies until 4-6 weeks after 
inoculation. While IgM antibodies are 
visible earlier, they are also more likely to 
yield a false positive result if used to 
diagnose acute Lyme disease in patients 
with more than four weeks of symptoms.  
Multiple sclerosis, amyotrophic lateral 
sclerosis, autoimmune disorders, other 
spirochetal diseases, and influenza may also 
cause false-positive results. Both IgM and 
IgG Western blots are susceptible to false 
negative results, in which the antibody titer 
is too low to produce a positive result on the 
test.  
The criteria for interpreting a blot as 
positive for anti-Borrelia antibodies depend 
on whether the antibody being tested for is 
IgM or IgG. According to CDC guidelines: 
• Positive IgM: has bands in at least 2 of 
the following regions: 24kDa (OspC); 
39kDa (BmpA); 41kDa (Fla).  
• Positive IgG: has bands in at least 5 of 
the following regions: 18kDa; 21kDa 
(OspC); 28kDa; 30kDa; 39kDa (BmpA); 
41kDa (Fla); 45kDa; 58kDa; 66kDa; and 
93kDa.  
Two positive bands for IgM and/or five 
positive bands for IgG are the minimum 
serologic criteria for the diagnosis of Lyme 
disease. There are no “partial positive” or 
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“partial negative” results. In the event of a 
positive test result, clinical correlation is 
required to provide context for final 
interpretation.  
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